We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Study Leads to Improved Diagnosis of Inherited Heart Muscle Disease

By LabMedica International staff writers
Posted on 29 Aug 2016
Print article
In a groundbreaking study of Mendelian gene pathogenicity, using comparative population genetics, researchers have developed more accurate diagnostics for inherited cardiomyopathy. The approach improves interpretation of the medical significance of gene mutations in patients being tested for a genetic condition.

In the study, experts from the University of Oxford (Oxford, England, UK) and Royal Brompton Hospitale (London, UK) compared genetic data from nearly 8,000 patients who have cardiomyopathy (CM) with over 60,000 reference samples from the general population. The aim was to reassess the role that variants in different genes play in causing the condition.

The large CM patient data set was from the Oxford Molecular Genetics Laboratory and the Laboratory of Molecular Medicine, Partners HealthCare (Boston, USA) and was compared with a large general population data set from ExAC, a new database compiled by an international consortium led by the MacArthur Lab (USA).

Rare variants in genes that are typically associated with dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and arrhythmogenic right ventricular cardiomyopathy (ARVCM), were examined. The study found that rare variants in some of these genes were not more common among the CM patients than the general population. This shows they are unlikely to be valid disease-causing genes and that having rare gene variants is collectively more common than previously thought.

Only 8 of 48 genes previously implicated in DCM, and 2/3 of genes that are regularly screened for HCM, were found to be much more common among the CM patients, thus more likely to be disease-causing genes. As a result, a more targeted approach can be taken with increased confidence to provide a CM diagnosis if one of these gene variants is found. In the past, clinical labs may have taken a more conservative approach, meaning that patients might have received an inconclusive result.

CMs are the most common cause of sudden death in otherwise healthy young people. Since the condition can be genetic, relatives of CM patients often undergo heart tests. Those found to have no symptoms but have the same gene variant as their family member can be monitored and treated, often before the condition can be detected by currently used tests. Also currently, if genetic testing was inconclusive for a patient, immediate relatives usually receive life-long follow-up care.

Lead author Roddy Walsh, NIHR Royal Brompton Cardiovascular Biomedical Research Unit, said: “This study has major implications for other diseases with strong genetic components as researchers can apply the same techniques to other studies using the ExAC database. The huge reference data set gives us an unprecedented understanding of gene variation in a normal population, while the large collection of data from CM patients has allowed us to make new insights into the disease.”

BHF Professor Hugh Watkins, head of Radcliffe Department of Medicine, University of Oxford (UK), said: “These results will help diagnostic laboratories avoid testing genes that can't be interpreted reliably, and be more confident in interpreting variants in the genes that we have shown to be valid.”

Professor Stuart Cook, SingHealth Duke-NUS Academic Medical Centre in Singapore, and director of genetics, Royal Brompton & Harefield NHS Foundation Trust, said: “This helps us pinpoint the variants that are causing the disease and identify parts of protein that are hotspots for the mutations. When we can be firmer in our diagnosis we no longer have to carry out follow-up tests for those who don't need it.”

The study, by Walsh R et al, was published online August 17, 2016, in the journal Genetics in Medicine.

Related Links:
University of Oxford
Royal Brompton Hospitale
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.